tislelizumab + anlotinib

Tislelizumab + anlotinib is a combination therapy consisting of two distinct agents: tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody immune checkpoint inhibitor, and anlotinib, a novel small molecule multi-target tyrosine kinase inhibitor. Tislelizumab blocks the PD-1 receptor on T cells to enhance anti-tumor immune responses by preventing tumor-mediated immune evasion. Anlotinib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including VEGFR, FGFR, c-KIT, c-MET, and RET. The combination aims to synergistically improve anti-tumor efficacy by both enhancing immune activation (via PD-1 blockade) and disrupting tumor vasculature (via angiogenesis inhibition). This regimen has been investigated in several cancer types—including advanced pancreatic ductal adenocarcinoma (as second-line therapy), triple-negative breast cancer (as neoadjuvant treatment), and small cell neuroendocrine carcinoma of the prostate—often in combination with chemotherapy[1][3][4][5].

Brand names

FukanghuaTevimbra

Other names

anlotinib combined with tislelizumab